<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0101-5907</journal-id>
<journal-title><![CDATA[Revista Paraense de Medicina]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Para. Med.]]></abbrev-journal-title>
<issn>0101-5907</issn>
<publisher>
<publisher-name><![CDATA[Fundação Santa Casa de Misericórdia do Pará]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0101-59072006000100009</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[O papel do vírus epstein barr na etiopatogenia do lúpus eritematoso sistêmico]]></article-title>
<article-title xml:lang="en"><![CDATA[The influence of epstein-barr virus in systemic lupus erythematosus etiology]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Kominsky]]></surname>
<given-names><![CDATA[Samuel]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Amorim]]></surname>
<given-names><![CDATA[Roberto]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Monteiro]]></surname>
<given-names><![CDATA[Elaine]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Abouhana]]></surname>
<given-names><![CDATA[Rui]]></given-names>
</name>
<xref ref-type="aff" rid="A04"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Coêlho]]></surname>
<given-names><![CDATA[Maria Rosângela Cunha Duarte]]></given-names>
</name>
<xref ref-type="aff" rid="A05"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Depto. de Medicina Clínica,UFPE  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A02">
<institution><![CDATA[,Depto. de Medicina Clínica,UFPE Médico, Pós-Residente, Disciplina de Reumatologia,UFPE ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A03">
<institution><![CDATA[,Médica Residente, Disciplina de Reumatologia,UFPE  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A04">
<institution><![CDATA[,Médico Residente, Disciplina de Reumatologia,UFPE  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A05">
<institution><![CDATA[,Profa.Doutora, Depto. de Fisiologia e Farmacologia, UFPE Setor de Virologia do Laboratório de Imunopatologia Keizo-Asami (LIKA),UFPE ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2006</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2006</year>
</pub-date>
<volume>20</volume>
<numero>1</numero>
<fpage>53</fpage>
<lpage>55</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_arttext&amp;pid=S0101-59072006000100009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_abstract&amp;pid=S0101-59072006000100009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_pdf&amp;pid=S0101-59072006000100009&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[OBJETIVO: explicar de que maneira o VEB pode atuar na etiopatogenia do LES. MÉTODO: realização de revisão da literatura utilizando os trabalhos recentes sobre o assunto. CONSIDERAÇÕES FINAIS: o VEB pode desencadear alterações auto-imunes, assim como pode anteceder as manifestações clínicas e imunológicas do LES, portanto tem papel importante na sua etiologia.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Many are the theories that try to link systemic lupus eyithematosus(LES) to viral infections virais, and Epstein- Barr virus(SLE) is the main. OBJECTIVE: For to explain how EBV can act in SLE aetiolog. CONCLUSION: EBV can excite auto-imune disorders, as well as can antecede the emergence of clinical and immunological manifestation of SLE. So EBV seem to play important role in SLE.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[lúpus eritematoso sistêmico]]></kwd>
<kwd lng="pt"><![CDATA[vírus Epstein Barr]]></kwd>
<kwd lng="pt"><![CDATA[patogenia]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p align="right"><font size="2" face="Verdana"><b><a name="topo"></a>ATUALIZA&Ccedil;&Atilde;O/REVIS&Atilde;O</b></font></p>     <p>&nbsp;</p>     <p><font size="4" face="Verdana"><b>O papel do v&iacute;rus epstein barr na etiopatogenia    do l&uacute;pus eritematoso sist&ecirc;mico</b></font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>The influence of epstein-barr virus in systemic    lupus erythematosus etiology</b></font></p>     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana"><b>Samuel Kominsky<sup>I</sup>; Roberto Amorim<sup>II</sup>; Elaine    Monteiro<sup>III</sup>; Rui Abouhana<sup>IV</sup>; Maria Ros&acirc;ngela Cunha Duarte Co&ecirc;lho<sup>V</sup></b></font></p>     <p><font size="2" face="Verdana"><sup>I</sup>Prof. Doutor, Depto. de Medicina Cl&iacute;nica,UFPE    <br>   <sup>II</sup>M&eacute;dico, P&oacute;s-Residente, Disciplina de Reumatologia,UFPE    ]]></body>
<body><![CDATA[<br>   <sup>III</sup>M&eacute;dica Residente, Disciplina de Reumatologia,UFPE    <br>   <sup>IV</sup>M&eacute;dico Residente, Disciplina de Reumatologia,UFPE    <br>   <sup>V</sup>Setor de Virologia do Laborat&oacute;rio de Imunopatologia Keizo-Asami    (LIKA),UFPE. Profa.Doutora, Depto. de Fisiologia e Farmacologia, UFPE</font></p>     <p><font size="2" face="Verdana"><a href="#endereco">Endere&ccedil;o para correspond&ecirc;ncia</a></font></p>     <p>&nbsp;</p>     <p>&nbsp;</p> <hr size="1" noshade>     <p><font size="2" face="Verdana"><b>RESUMO</b></font></p>     <p><font size="2" face="Verdana"><b><i>OBJETIVO:</i></b><i> explicar de que maneira    o VEB pode atuar na etiopatogenia do LES.    <br>   <b>M&Eacute;TODO:</b> realiza&ccedil;&atilde;o de revis&atilde;o da literatura    utilizando os trabalhos recentes sobre o assunto.    <br>   <b>CONSIDERA&Ccedil;&Otilde;ES FINAIS:</b> o VEB pode desencadear altera&ccedil;&otilde;es    auto-imunes, assim como pode anteceder as manifesta&ccedil;&otilde;es cl&iacute;nicas    e imunol&oacute;gicas do LES, portanto tem papel importante na sua etiologia.</i></font></p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana"><b>Descritores:</b> l&uacute;pus eritematoso    sist&ecirc;mico, v&iacute;rus Epstein Barr, patogenia.</font></p> <hr size="1" noshade>     <p><font size="2" face="Verdana"><b>SUMMARY</b></font></p>     <p><font size="2" face="Verdana">Many are the theories that try to link systemic    lupus eyithematosus(LES) to viral infections virais, and Epstein- Barr virus(SLE)    is the main.    <br>   <b>OBJECTIVE:</b> For to explain how EBV can act in SLE aetiolog.    <br>   <b>CONCLUSION:</b> EBV can excite auto-imune disorders, as well as can antecede    the emergence of clinical and immunological manifestation of SLE. So EBV seem    to play important role in SLE.</font></p> <hr size="1" noshade>     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>INTRODU&Ccedil;&Atilde;O</b></font></p>     <p><font size="2" face="Verdana">O L&uacute;pus Eritematoso Sist&ecirc;mico (LES)    &eacute; uma   doen&ccedil;a auto-imune de etiologia desconhecida, na   qual os auto-anticorpos encontram-se,   universalmente, presentes. Os mecanismos   respons&aacute;veis pela produ&ccedil;&atilde;o e perpetua&ccedil;&atilde;o    dessa   resposta imune aberrante permanecem pouco   esclarecidos <sup>1,2</sup>. Em sua etiologia variada est&atilde;o   inclu&iacute;das altera&ccedil;&otilde;es imunol&oacute;gicas acarretando a   produ&ccedil;&atilde;o de auto anticorpos, a&ccedil;&atilde;o de fatores   gen&eacute;ticos, ambientais (radia&ccedil;&atilde;o ultra violeta), v&iacute;rus,   drogas, horm&ocirc;nios e estresse<sup>3</sup>.</font></p>     <p><font size="2" face="Verdana">Dentre os prov&aacute;veis fatores etiol&oacute;gicos    ou   etiopatog&ecirc;nicos do LES, a infec&ccedil;&atilde;o viral tem sido   largamente estudada. Os v&iacute;rus desempenham um   papel importante nas doen&ccedil;as auto-imunes e um dos   mais freq&uuml;entemente citados, como desencadeante   ou agravante das altera&ccedil;&otilde;es auto-imunes, &eacute; o v&iacute;rus   Epstein Barr (EBV)<sup>4</sup>.</font></p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana">O EBV &eacute; um herpesv&iacute;rus que infecta    mais de   90% da popula&ccedil;&atilde;o mundial, sendo o agente   etiol&oacute;gico da mononucleose infecciosa. O ciclo viral,   no interior do hospedeiro, inclui um per&iacute;odo de   lat&ecirc;ncia e um de virul&ecirc;ncia no qual os v&iacute;rus podem emergir    em quantidade suficiente para causar   estimula&ccedil;&atilde;o imune<sup>5</sup>.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>OBJETIVO</b></font></p>     <p><font size="2" face="Verdana">Explicar de que maneira o VEB pode atuar na   etiopatogenia do LES.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>M&Eacute;TODO</b></font></p>     <p><font size="2" face="Verdana">Revis&atilde;o da literatura utilizando os trabalhos   recentes sobre o assunto.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>DISCUSS&Atilde;O</b></font></p>     <p><font size="2" face="Verdana"><b>L&uacute;pus eritematoso sist&ecirc;mico e    v&iacute;rus epstein-barr</b></font></p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana">A associa&ccedil;&atilde;o entre infec&ccedil;&atilde;o    pelo EBV e LES tem sido descrita por diversos autores, bem como a rea&ccedil;&atilde;o    cruzada de anticorpos contra constituintes prot&eacute;icos virais e humanos<sup>6,7</sup>.    A suspeita de tal associa&ccedil;&atilde;o foi refor&ccedil;ada pelo achado    de altos t&iacute;tulos de anticorpos anti-EBV em pacientes com LES<sup>8</sup>,    assim como, pela constata&ccedil;&atilde;o de que a infec&ccedil;&atilde;o pelo    EBV antecede o aparecimento das altera&ccedil;&otilde;es auto-imunes, que ocorrem    no LES<sup>4,7</sup>. Um aumento da preval&ecirc;ncia de infec&ccedil;&otilde;es    pelo EBV em pacientes jovens, portadores de LES, parece confirmar tais observa&ccedil;&otilde;es<sup>9</sup>.</font></p>     <p><font size="2" face="Verdana"><b>Patogenia</b></font></p>     <p><font size="2" face="Verdana">Na literatura, tem sido sugerido que o EBV   apresenta-se mais como uma das causas do que como   conseq&uuml;&ecirc;ncia das anormalidades da resposta imune   induzidas pelo LES. O EBV pode ser capaz de   infectar popula&ccedil;&otilde;es de linf&oacute;citos B auto-reativos,   perpetuando sua presen&ccedil;a em tais c&eacute;lulas, al&eacute;m de   causar sua expans&atilde;o mediante a indu&ccedil;&atilde;o de   prolifera&ccedil;&atilde;o e diferencia&ccedil;&atilde;o celular. Usualmente    os   linf&oacute;citos T citot&oacute;xicos s&atilde;o capazes de eliminar   linf&oacute;citos B infectados pelo EBV, durante o processo   de replica&ccedil;&atilde;o celular. No entanto c&eacute;lulas B de   mem&oacute;ria com genoma viral podem sobreviver por   longos per&iacute;odos<sup>10</sup>.</font></p>     <p><font size="2" face="Verdana">A persist&ecirc;ncia de linf&oacute;citos B infectados    pelo   EBV, bem como a presen&ccedil;a de linf&oacute;citos T autoreativos   poderia decorrer de uma falha no mecanismo   de apoptose. O sistema Fas/Fas-ligante &eacute; um   mecanismo para manuten&ccedil;&atilde;o da toler&acirc;ncia perif&eacute;rica,   ou seja, &eacute; capaz de induzir apoptose em linf&oacute;citos   anormais presentes na circula&ccedil;&atilde;o<sup>11</sup>. Assim um defeito   no gene Fas pode ser um dos fatores relacionados   com a persist&ecirc;ncia de linf&oacute;citos auto-reativos,   respons&aacute;veis pelas altera&ccedil;&otilde;es auto-imunes<sup>12</sup>.</font></p>     <p><font size="2" face="Verdana">Os linf&oacute;citos B infectados pelo EBV geralmente    n&atilde;o s&atilde;o destru&iacute;dos por linf&oacute;citos T e por c&eacute;lulas    NK, podendo permanecer em repouso ou replicar, sem serem eliminados por meio    destas c&eacute;lulas. &Eacute; prov&aacute;vel que a regula&ccedil;&atilde;o    negativa da prote&iacute;na classe I do MHC, nas c&eacute;lulas infectadas,    seja um dos principais respons&aacute;veis pelo mecanismo de escape de sua destrui&ccedil;&atilde;o<sup>13</sup>.    Dessa maneira, a infec&ccedil;&atilde;o pelo EBV pode causar expans&atilde;o    clonal linf&oacute;citos T auto-reativos que por sua vez auxiliariam os linf&oacute;citos    B auto-reativos na produ&ccedil;&atilde;o de auto-anticorpos, bem como na perpetua&ccedil;&atilde;o    das respostas auto-imunes<sup>10</sup>.</font></p>     <p><font size="2" face="Verdana">A produ&ccedil;&atilde;o de auto-anticorpos normalmente   requer a presen&ccedil;a de linf&oacute;citos T auto-reativos, visto   serem estas c&eacute;lulas de fundamental import&acirc;ncia para   a ativa&ccedil;&atilde;o de linf&oacute;citos B. Os linf&oacute;citos T auto-reativos   devem desempenhar papel importante, uma   vez que a presen&ccedil;a de imunoglobulinas do tipo IgG,   de alta afinidade contra constituintes nucleares requer   a presen&ccedil;a dessas c&eacute;lulas em associa&ccedil;&atilde;o com   linf&oacute;citos B<sup>14</sup>.</font></p>     <p><font size="2" face="Verdana"><b>Outros fatores</b></font></p>     <p><font size="2" face="Verdana">Para que tais eventos se fa&ccedil;am presentes    al&eacute;m da perda da toler&acirc;ncia, os pacientes deveriam apresentar predisposi&ccedil;&atilde;o    gen&eacute;tica que, associada a fatores ambientais como presen&ccedil;a de    EBV latente em linf&oacute;citos B favoreceria o surgimento das altera&ccedil;&otilde;es    auto-imunes presentes no LES<sup>35</sup>. Tais fatores podem atuar na perpetua&ccedil;&atilde;o    da resposta imune anormal, uma vez que linf&oacute;citos T auto-reativos podem    surgir ap&oacute;s infec&ccedil;&atilde;o viral, sem, no entanto, causar dano    tissular ou provocar resposta imune anormal e conseq&uuml;ente les&atilde;o    tecidual<sup>16</sup>.</font></p>     <p><font size="2" face="Verdana">Para explicar esse processo, de uma forma mais   ampla, deveria haver: o envolvimento de   predisposi&ccedil;&atilde;o gen&eacute;tica, fator ambiental, perda da   toler&acirc;ncia imunol&oacute;gica, a presen&ccedil;a de genes que   controlam a produ&ccedil;&atilde;o de citocinas, genes que   regulam o mecanismo de apoptose, mecanismos   respons&aacute;veis pela dele&ccedil;&atilde;o de linf&oacute;citos auto-reativos,   genes que facilitam a perpetua&ccedil;&atilde;o de linf&oacute;citos   infectados e os mecanismos de evas&atilde;o que o EBV   possui para que n&atilde;o seja reconhecido pelo linf&oacute;cito   T citot&oacute;xico.</font></p>     <p><font size="2" face="Verdana">Trabalhos sugerem que a infec&ccedil;&atilde;o    viral e as   altera&ccedil;&otilde;es imunol&oacute;gicas do LES poderiam anteceder   o aparecimento cl&iacute;nico da doen&ccedil;a, al&eacute;m dos pacientes   com LES apresentarem defici&ecirc;ncias na capacidade   de elimina&ccedil;&atilde;o do EBV. Outros sugerem a   simultaneidade do in&iacute;cio do LES com a replica&ccedil;&atilde;o   viral<sup>4,7</sup>.</font></p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>CONSIDERA&Ccedil;&Otilde;ES FINAIS</b></font></p>     <p><font size="2" face="Verdana">O V&iacute;rus Epstein-Barr apresenta-se como    uma   das principais causas das anormalidades da resposta   imune induzidas pelo LES. Al&eacute;m disso, para a   perpetua&ccedil;&atilde;o das altera&ccedil;&otilde;es e desenvolvimento do   LES, s&atilde;o necess&aacute;rios, predisposi&ccedil;&atilde;o gen&eacute;tica,    fator   ambiental, perda da toler&acirc;ncia imunol&oacute;gica. Portanto,   o EBV apesar de sua import&acirc;ncia na etiopatog&ecirc;nia   do LES, n&atilde;o pode ser responsabilizado como &uacute;nico   fator etiol&oacute;gico.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>REFER&Ecirc;NCIAS</b></font></p>     <!-- ref --><p><font size="2" face="Verdana">1. JAMES J&Aacute;, NEAS BR, MOSER KL, HALL T,    BRUNER GR, SESTAK AL, HARLEY JB. Systemic lupus erythematosus in adults is associated    with previous Epstein-Barr virus exposure.<i>Arthritis Rheum</i>. Vol. 44 (5)p    1122-1126, 2001.</font><!-- ref --><p><font size="2" face="Verdana">2. JACOBSON DL, GANGE SJ, ROSE NR, GRAHAM NMH.    Epidemiology and estimated population burdenof selected autoimmune diseases    in the United States. <i>Clin Immunol Immunopathol</i>. Vol.84 p.223-243, 1997.</font><!-- ref --><p><font size="2" face="Verdana">3. PHALEN MKF. Progress on Lupus: new clarity    for baffling disease. E Mednews (on line) <a href="www.ama-assn.org">www.ama-assn.org</a>.</font><!-- ref --><p><font size="2" face="Verdana">4. VERDOLINI R, BUGATTI L, GIANGIACOMI M, NICOLINE    M, FILOSA G, C&Eacute;RIO R. SYSTEMIC. lupus erythematosus induced by Epstein-Barr    virus infeccion. <i>BR J Dermatol</i>.Vol146 (5)p.877-881,2002.</font><!-- ref --><p><font size="2" face="Verdana">5. MCCLAIN MT, HAPP EC, HARLEY JB, JAMES J&Aacute;.    Anti-Sm autoantibodies in systemic lupus target highly basic surface structures    of complexed spliceosomal autoantigens. <i>J Immunol</i>.Vol 168. p. 2054-2062,    2002.</font><!-- ref --><p><font size="2" face="Verdana">6. KATZ BZ, SALIM IB, KIM S, NSIAH-KUMI P, WEINEL    W. Epstein-Barr virus burde in adolescents with systemic lupus erythematosus.    <i>Pediatr Infect Dis J</i> Vol 20(2)p.148-153, 2001.</font><!-- ref --><p><font size="2" face="Verdana">7. DROR Y, BLACHAR Y, COHEN P, LIVNI N, ROSENMANN    E, ASHKENAZI A. Systemic lupus erytematosus associated with acute Epstein-Barr    virus infeccion. <i>Am J Kidney Dis</i>.Vol 32(5)p. 825-828.1998.</font><!-- ref --><p><font size="2" face="Verdana">8. ORIGGI L, PEREGO R, HU C, BERTETTI E, D'AGOSTINO    P, ASERO R, RIBOLDI P. Anti-Epstein-Barr v&iacute;rus antibodies in systemic    lupus erythematosus. <i>Boll Ist Sieroter Millan</i>.Vol 67(2)p.116-122,1988.</font><!-- ref --><p><font size="2" face="Verdana">9. JAMES J&Aacute;, KAUFEMAN KM, FARRIS AD, TAYLOR-ALBERT    E, LEHMAN TJA, HARLEY JB. An increased prevalence of Epstein-Barr virus infection    in young patients suggests a possible etiology for systemic lupus erythematosus.    <i>J Clin Invest</i>. Vol 100(12)p.3019-3026,1997.</font><!-- ref --><p><font size="2" face="Verdana">10. THORLEY-LAWSON DA. Epstein-Barr virus: exploiting    the immune-sytem. <i>Nat Rev Immunol</i>. Vol. 1p.75-82,2001.</font><!-- ref --><p><font size="2" face="Verdana">11. VAN PARIJS L, ABBAS AK. Role of Fas-mediated    cell death in the regulation of immune responses. <i>Curr Opin Immuno</i>. Vol    8p.355-361,1996.</font><!-- ref --><p><font size="2" face="Verdana">12. WU J, ZHOU T, ZHANG J et al. Correction of    accelerated autoimmune disease by early replacement of mutated Ipr gene with    the normal Fas apoptosis gene in the cells of transgenic MRL-Ipr/Ipr Mice. <i>Proc    Natl Acad Sci USA</i>.Vol 91,p.2344-2348,1994.</font><!-- ref --><p><font size="2" face="Verdana">13. LI F et al. Reduced expression of peptide-loaded    HLA class I molecules on multiple sclerosis lymphocytes. <i>Ann Neurol</i>.    vol 38 p.147-154,1995.</font><!-- ref --><p><font size="2" face="Verdana">14. SHEDLOCK DJ, SHEN H. Requirement for CD4    T cell help in generating functional CD8 T cell memory. <i>Science</i>. Vol.    300(5617)p.337-339. 2003.</font><!-- ref --><p><font size="2" face="Verdana">15. PENDER MP. Infeccion of autoreactive B lymphocytes    with EBV,causing chronic autoimmune disease. <i>Trends Immunol</i>.Vol 24(11)2003.</font><!-- ref --><p><font size="2" face="Verdana">16. PENDER MP. Activation- induced apoptosis    of auto reactive and alloreactive T lymphocytes in the target organ as a major    mechanism of tolerance. <i>Immunol Cell Biol</i>. Vol 77 p.216-223,1999.</font><p>&nbsp;</p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana"><b><a name="endereco"></a><a href="#topo"><img src="/img/revistas/rpm/v20n1/seta.gif" border="0"></a>    Endere&ccedil;o para correspond&ecirc;ncia:</b>    <br>   Dra. Maria Ros&acirc;ngela Cunha Duarte Co&ecirc;lho    <br>   Rua Manoel Lubambo, 118 - Afogados    <br>   Recife (PE)- CEP: 50.850-040    <br>   Fone : (081) 3271.85.86 . 3428 1651.    <br>   e-mail:<a href="mailto:rcoelho@lika.ufpe.br">rcoelho@lika.ufpe.br</a></font></p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana">Recebido em 30.01.2006    <br>   Aprovado em 29.03.2006</font></p>     <p>&nbsp;</p>      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[JAMES]]></surname>
<given-names><![CDATA[JÁ]]></given-names>
</name>
<name>
<surname><![CDATA[NEAS]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
<name>
<surname><![CDATA[MOSER]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[HALL]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[BRUNER]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[SESTAK]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[HARLEY]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure]]></article-title>
<source><![CDATA[Arthritis Rheum]]></source>
<year>2001</year>
<volume>44</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1122-1126</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[JACOBSON]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[GANGE]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[ROSE]]></surname>
<given-names><![CDATA[NR]]></given-names>
</name>
<name>
<surname><![CDATA[GRAHAM]]></surname>
<given-names><![CDATA[NMH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Epidemiology and estimated population burdenof selected autoimmune diseases in the United States]]></article-title>
<source><![CDATA[Clin Immunol Immunopathol]]></source>
<year>1997</year>
<volume>84</volume>
<page-range>223-243</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PHALEN]]></surname>
<given-names><![CDATA[MKF]]></given-names>
</name>
</person-group>
<source><![CDATA[Progress on Lupus: new clarity for baffling disease]]></source>
<year></year>
<publisher-name><![CDATA[E Mednews]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[VERDOLINI]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[BUGATTI]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[GIANGIACOMI]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[NICOLINE]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[FILOSA]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[CÉRIO]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[SYSTEMIC: lupus erythematosus induced by Epstein-Barr virus infeccion]]></article-title>
<source><![CDATA[BR J Dermatol]]></source>
<year>2002</year>
<volume>146</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>877-881</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MCCLAIN]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[HAPP]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[HARLEY]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[JAMES]]></surname>
<given-names><![CDATA[JÁ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Anti-Sm autoantibodies in systemic lupus target highly basic surface structures of complexed spliceosomal autoantigens]]></article-title>
<source><![CDATA[J Immunol]]></source>
<year>2002</year>
<volume>168</volume>
<page-range>2054-2062</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[KATZ]]></surname>
<given-names><![CDATA[BZ]]></given-names>
</name>
<name>
<surname><![CDATA[SALIM]]></surname>
<given-names><![CDATA[IB]]></given-names>
</name>
<name>
<surname><![CDATA[KIM]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[NSIAH-KUMI]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[WEINEL]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Epstein-Barr virus burde in adolescents with systemic lupus erythematosus]]></article-title>
<source><![CDATA[Pediatr Infect Dis J]]></source>
<year>2001</year>
<volume>20</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>148-153</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DROR]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[BLACHAR]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[COHEN]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[LIVNI]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[ROSENMANN]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[ASHKENAZI]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Systemic lupus erytematosus associated with acute Epstein-Barr virus infeccion]]></article-title>
<source><![CDATA[Am J Kidney Dis]]></source>
<year>1998</year>
<volume>32</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>825-828</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ORIGGI]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[PEREGO]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[HU]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[BERTETTI]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[D'AGOSTINO]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[ASERO]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[RIBOLDI]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Anti-Epstein-Barr vírus antibodies in systemic lupus erythematosus]]></article-title>
<source><![CDATA[Boll Ist Sieroter Millan]]></source>
<year>1988</year>
<volume>67</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>116-122</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[JAMES]]></surname>
<given-names><![CDATA[JÁ]]></given-names>
</name>
<name>
<surname><![CDATA[KAUFEMAN]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[FARRIS]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[TAYLOR-ALBERT]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[LEHMAN]]></surname>
<given-names><![CDATA[TJA]]></given-names>
</name>
<name>
<surname><![CDATA[HARLEY]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus]]></article-title>
<source><![CDATA[J Clin Invest]]></source>
<year>1997</year>
<volume>100</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>3019-3026</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[THORLEY-LAWSON]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Epstein-Barr virus: exploiting the immune-sytem]]></article-title>
<source><![CDATA[Nat Rev Immunol]]></source>
<year>2001</year>
<volume>1</volume>
<page-range>75-82</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[VAN PARIJS]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[ABBAS]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Role of Fas-mediated cell death in the regulation of immune responses]]></article-title>
<source><![CDATA[Curr Opin Immuno]]></source>
<year>1996</year>
<volume>8</volume>
<page-range>355-361</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[WU]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[ZHOU]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[ZHANG]]></surname>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Correction of accelerated autoimmune disease by early replacement of mutated Ipr gene with the normal Fas apoptosis gene in the cells of transgenic MRL-Ipr/Ipr Mice]]></article-title>
<source><![CDATA[Proc Natl Acad Sci USA]]></source>
<year>1994</year>
<volume>91</volume>
<page-range>2344-2348</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LI]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Reduced expression of peptide-loaded HLA class I molecules on multiple sclerosis lymphocytes]]></article-title>
<source><![CDATA[Ann Neurol]]></source>
<year></year>
<volume>38</volume>
<page-range>147-154</page-range><page-range>1995</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SHEDLOCK]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[SHEN]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Requirement for CD4 T cell help in generating functional CD8 T cell memory]]></article-title>
<source><![CDATA[Science]]></source>
<year>2003</year>
<volume>300</volume>
<numero>5617</numero>
<issue>5617</issue>
<page-range>337-339</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PENDER]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Infeccion of autoreactive B lymphocytes with EBV,causing chronic autoimmune disease]]></article-title>
<source><![CDATA[Trends Immunol]]></source>
<year>2003</year>
<volume>24</volume>
<numero>11</numero>
<issue>11</issue>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PENDER]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Activation- induced apoptosis of auto reactive and alloreactive T lymphocytes in the target organ as a major mechanism of tolerance]]></article-title>
<source><![CDATA[Immunol Cell Biol]]></source>
<year>1999</year>
<volume>77</volume>
<page-range>216-223</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
